Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Overview of attention for article published in New England Journal of Medicine, December 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 63 news outlets
blogs: 2 blogs
policy: 3 policy sources
twitter: 112 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
reddit: 1 Redditor
guideline: 5 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 291 Mendeley

So far, Altmetric has seen 120 X posts from 112 X users, with an upper bound of 1,006,887 followers.

@chaseg1698 @SwaledaleMutton https://t.co/aLTzWbuamt It is unethical to deny people the standard of treatment in a clinical trial. This includes for other drugs. https://t.co/rxjzwhXyDa https://t.co/pvvXVwHPoV https://t.co/pLuiQUlccT

RT @NEJM: A phase 3 study compared ibrutinib with the more specific BTK inhibitor zanubrutinib in patients with relapsed CLL. At 2 years, p…

#Zanubrutinib or #Ibrutinib in Relapsed or Refractory #ChronicLymphocyticLeukemia Zanubrutinib with #obinutuzumab was better than either one alone 👉https://t.co/a9pZ6Xmsuk @NEJM @Mshadman https://t.co/XmS4WdTzYW

RT @Eddie_Cliff: Great slide comparing BTKi toxicities in the head-to-head trials Elevate RR (https://t.co/lSDHEfMSpl) and Alpine (https://…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 116 additional X posts.